Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy maintains an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS) and keeps the price target at $100.
July 23, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Colleen Kusy maintains an Outperform rating on Apellis Pharmaceuticals and keeps the price target at $100.
The reaffirmation of an Outperform rating and a $100 price target by a reputable analyst is likely to boost investor confidence in Apellis Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100